This morning, Peregrine Pharmaceuticals (NASDAQ:PPHM) released additional details regarding its revised analysis of bavituximab in non-small cell lung cancer. Today's release comes less than a week after investors totally misinterpreted clinical data on the drug used in pancreatic cancer, initially bidding up shares before a sharp sell-off later in the day. As Brenton Flynn outlines in the video below, this time around the investor reaction has been much more rational.
Brenton Flynn has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.